← Back to Clinical Trials
Recruiting NCT07200674

NCT07200674 Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07200674
Status Recruiting
Phase
Sponsor University Hospital, Strasbourg, France
Condition Hypertriglyceridemia
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2024-03-11
Primary Completion 2025-12-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2024-03-11 with a primary completion date of 2025-12-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Some hemostasis techniques require spectrophotometric measurements. These are then subject to interference from the sample's lipemia (postprandial, hypertriglyceridemia, etc.), which risks distorting the results; this is estimated to affect 0.5 to 2.5% of samples. This is particularly the case for anti-Xa activity, a critical test used to monitor anticoagulant treatments. To date, the HUS Hematology Laboratory does not have or is aware of any alternative method to overcome this interference, and is unable to perform anti-Xa activity when the sample has excessive lipemia. This study will evaluate, on samples from routine care artificially overloaded with lipids, the effectiveness of a high-speed centrifugation process (10,800g for 10 minutes).

Eligibility Criteria

Inclusion Criteria: * Adult patient (≥ 18 years) * Patient anticoagulated with an anti-Xa (UFH, LMWH, fondaparinux, danaparoid, apixaban, rivaroxaban) * Sample sent to the HUS Hematology Laboratory and analyzed for measurement of the anti-Xa activity of an anticoagulant as part of routine care Exclusion Criteria: * Patient with a basal lipidemic sample * Sample of insufficient volume

Contact & Investigator

Central Contact

Agathe HERB, PharmD

✉ agathe.herb@chru-strasbourg.fr

📞 33 3 88 12 75 53

Frequently Asked Questions

Who can join the NCT07200674 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertriglyceridemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07200674 currently recruiting?

Yes, NCT07200674 is actively recruiting participants. Contact the research team at agathe.herb@chru-strasbourg.fr for enrollment information.

Where is the NCT07200674 trial being conducted?

This trial is being conducted at Strasbourg, France.

Who is sponsoring the NCT07200674 clinical trial?

NCT07200674 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology